Study shows that people whose mother had a history of Alzheimer’s disease had a greater risk for the disease compared with ...

The clearance adds a Centiloid scale tool to GE Healthcare’s Mim software to help clinicians determine the density of amyloid ...

Researchers discover how amyloid-β and tau pathologies interact to drive early neurophysiological changes and cognitive ...

After more than a century since Alois Alzheimer's description of an “unusual illness of the cerebral cortex”, the development ...

With FDA 510(k) clearance, MIMneuro may perform positron emission tomography-based imaging analysis of amyloid plaque, GE ...

GE HealthCare’s MIM Software receives US FDA clearance of new Centiloid scaling tool to quantify amyloid plaque in brain imaging: Chicago Thursday, September 19, 2024, 12:00 Hrs ...

A study published Wednesday in Nature Neuroscience sheds light into how amyloid-beta and tau proteins impact brain activity ...

GE Healthcare's MIM Software announces the receipt of FDA clearance for its Centiloid scaling tool to perform PET-based ...

aDementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, UK bDepartment of Clinical and Movement Neurosciences, Queen Square Brain Bank for Neurological ...

The GE HealthCare imaging tool is coming out as pharma companies release new therapies onto the market to help treat the ...

GE HealthCare’s recently acquired MIM Software division has secured an FDA clearance for a tool to help quantify the density ...